The Diagnostic Imaging mammography modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of mammography, including 2D digital mammography, digital breast tomosynthesis, and breast ultrasound.
June 7th 2023
Five artificial intelligence (AI) algorithms for mammography assessment were better at predicting breast cancer risk over five years than the Breast Cancer Surveillance Consortium (BCSC) risk model, according to new retrospective research involving over 13,000 women.
New ACR Guidelines Emphasize Earlier Mammography Screening for High-Risk WomenMay 4th 2023
While calling for a universal breast cancer risk assessment by the age of 25, the American College of Radiology (ACR) emphasized that ascertaining screening needs prior to the age of 40 is particularly important in high-risk populations such as Black women, who are 42 percent more likely to die from breast cancer in comparison to non-Hispanic White women.
What a New Study Reveals About AI, Bias and Mammography AssessmentMay 2nd 2023
Regardless of experience level, radiologists are likely to be affected by automation bias when utilizing adjunctive artificial intelligence (AI) for mammography interpretation, according to newly published research.
Should Race and Ethnicity Factor into Starting Ages for Mammography Screening?April 20th 2023
Emerging research looking at data from over 414,000 cases of breast cancer deaths suggests that Black women should begin annual mammography screening seven to nine years earlier than White women.
Does Timing of Imaging Affect Interpretation of Contrast-Enhanced Mammography?April 19th 2023
Earlier initiation of imaging after contrast administration with contrast-enhanced mammography may provide better visibility of lesions and conspicuity against background parenchymal enhancement, according to new research presented at the American Roentgen Ray Society (ARRS) 2023 Annual Meeting in Honolulu, Hawaii.
Is There More Appropriate Use of BI-RADS Category 3 with DBT than Mammography in Patients with Breast Cancer History?April 14th 2023
Recent research involving nearly 15,000 mammography exams in patients with a personal history of breast cancer revealed that digital breast tomosynthesis (DBT) was associated with a lower frequency of BI-RADS category 3 assessment and a lower malignancy rate for BI-RADS 3 lesions in comparison to full-field digital mammography.
Study Looks at Contributing Factors to Incomplete Follow-Up for BI-RADS 3 FindingsApril 6th 2023
Emerging research suggests that 29 percent of patients with index breast magnetic resonance imaging (MRI) exams, 45 percent of Asian women and 30 percent of women living in the highest disadvantaged neighborhoods did not have follow-up imaging after a BI-RADS 3 diagnosis.
Can ChatGPT Provide Appropriate Information on Mammography and Other Breast Cancer Screening Topics?April 5th 2023
Researchers found that ChatGPT offered appropriate responses to 22 out of 25 patient-oriented questions on mammography screening, dense breasts, BI-RADS scoring and other topics related to breast cancer screening and prevention.
Automated Breast Ultrasound: Is it a Viable Second-Look Option for Women with Dense Breasts?April 4th 2023
Emerging research shows the adjunctive use of automated breast ultrasound with mammography has similar sensitivity for breast cancer detection as adjunctive handheld ultrasound but may offer reduced false-positive rates in women with dense breasts.
Study: Emerging AI Platform for DBT Shows 23 Percent Increase in Breast Cancer Detection RateMarch 23rd 2023
In a recent video interview, Kathy Schilling, M.D., discussed findings from a study of ProFound AI, an adjunctive artificial intelligence (AI) software for digital breast tomosynthesis (DBT), that demonstrated a 23 percent increase in breast cancer detection in comparison to DBT alone.
Mammography Study Shows 22 Percent Higher Incidence of Dense Breasts in Women with a Family History of Breast CancerMarch 13th 2023
Newly published retrospective research involving a large database of premenopausal women in Korea showed that women were 64 percent more likely to have dense breasts if their mother and a sister had breast cancer.
FDA Issues Final Rule on National Breast Density Notification for Mammography ReportsMarch 9th 2023
As part of updates to the Mammography Quality Standards Act (MQSA) of 1992, the Food and Drug Administration (FDA) has issued a final rule that requires the inclusion of breast density assessment in mammography reports starting on September 10, 2024.
Study: AI Improves Cancer Detection Rate for Digital Mammography and Digital Breast TomosynthesisMarch 6th 2023
Comparing year-long findings with and without adjunctive artificial intelligence (AI) at a breast cancer screening program in Spain, researchers found the combination of digital breast tomosynthesis and AI had a 92.5 percent accuracy for diagnosing cancer in patients with elevated risk.
Cancer Screenings and COVID-19: What a New Study ShowsFebruary 27th 2023
New research from the American Cancer Society comparing pre-pandemic cancer screening prevalence to the second year of the COVID-19 pandemic in the United States showed a 1.1 million decrease in breast cancer screenings, a 4.4 million decrease in cervical cancer screening and a 600,000 decrease in prostate cancer screenings.
Mammography Screening Intervals and DCIS: What a New Study RevealsFebruary 24th 2023
In a new study involving over 900,000 women, researchers found the cumulative six-year risk of mammography screening-detected ductal carcinoma in situ (DCIS) increased with shorter screening intervals and age.
Interval Breast Cancer: What a New Mammography Study RevealsFebruary 6th 2023
In a new study of 1,232 women diagnosed with breast cancer within a year of a screening mammography exam, researchers found that interval breast cancer was 17 percent more likely in women with dense or extremely dense breasts, and over three times more likely to involve stage 2 or higher primary tumors in comparison to screening-detected breast cancer.